The Pritzker Neuropsychiatric Disorders Research Consortium seeks to discover the neurobiological and genetic causes of three major psychiatric disorders, Major Depressive Disorder, Bipolar Disorder and Schizophrenia. The Pritzker Consortium also seeks to identify biomarkers and novel targets for drug development. The Consortium conducts studies to identify genetic alterations in brain circuits associated with mood disorders and consists of investigators involved in all aspects of the scientific process from basic to clinical research, from genetics to neuroscience. The multi-dimensional approach is also bi-directional, in that the research process starts with human postmortem brain tissue proceeds to animal models and circles back to individuals with psychiatric disorders to translate our knowledge into benefits for patients.
The Pritzker Consortium has made several significant accomplishments that fuel the translational approach to discover biomarkers and novel targets for the treatment of psychiatric disorders. The Consortium consists of a community of over 100 scientists across 5 institutions performing collaborative research using state-of-the-art techniques to tackle psychiatric disorders. The Consortium has the infrastructure for clinical neuroimaging and phenotyping studies, brain and blood collection, neuroanatomical studies, gene expression, genotyping studies and bioinformatics, as well as animal studies in rodents and non-human primates.